Travad

Quick links to important sections

Travad

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Travad

Property Description
Active ingredient Monosodium Phosphate
Form Rectal Solution (Enema)
Pharmacological class Saline Laxative
General purpose Relief of Occasional Constipation
Origin Synthetic (Inorganic Compound)

What Type of Medicine is Travad? (Identity and Classification)

Travad is a trade name for a specific pharmaceutical preparation formally classified as a Saline Laxative. Its core active ingredient is Monosodium Phosphate, chemically known as Sodium Dihydrogen Phosphate (NaH2PO4).

The medicine is categorized as an inorganic compound that is synthetic in origin and relies on a physical mechanism for its effect. This classification is clinically recognized by major pharmacological bodies and is consistent with the established mechanism of phosphate salts. The formulation frequently involves the combination of Monosodium Phosphate with Disodium Phosphate to achieve the necessary osmotic balance. The general function of this product is rooted in the local action of these salts within the bowel.


Composition, Form, and General Purpose (Physical and Functional Identity)

The preparation marketed as Travad is most commonly supplied as a sterile, ready-to-use Rectal Solution (enema), designed for administration via the rectal route. The active sodium phosphates are dissolved in an aqueous liquid solution that serves as the primary vehicle.

This dosage form allows the sodium phosphates to create a strong osmotic gradient within the lower bowel, which draws a significant volume of water into the colon. Phosphate-based solutions are utilized for bowel evacuation, distinguishing this product from other laxative types. The overall general therapeutic purpose of this volume expansion is to physically stimulate the bowel wall, promoting a complete bowel movement for the relief of occasional constipation or for necessary pre-procedure bowel cleansing.

Regulatory References

  1. U.S. National Library of Medicine (NLM)

What side effects are possible with Travad?

Possible Side Effects and Safety Information

The officially documented safety profile of Travad (Sodium Phosphate Rectal Solution) is categorized by both common local reactions and a critical, rare risk of systemic complications linked to misuse or pre-existing conditions.


Official Adverse Reaction Categories

Adverse reactions are classified by frequency as observed in clinical use and post-marketing surveillance:

  • Common / More Common: These effects are typically confined to the gastrointestinal system and include nausea, stomach pain, and abdominal bloating.
  • Very Rare: Documented very rare events include hypersensitivity, dehydration, and severe electrolyte imbalances such as hyperphosphataemia, hypocalcaemia, and metabolic acidosis. Local reactions like rectal irritation or proctalgia (rectal pain) are also noted.

Serious Safety Considerations

The most serious adverse events are linked to excessive absorption or solution retention and can include life-threatening electrolyte shifts. These disturbances may lead to acute kidney injury (renal failure), arrhythmias (irregular heartbeat), seizures, and tetany. Regulatory documents note that fatalities have been reported when the product is used in contraindicated patient groups or at excessive doses.


Population-Specific Safety Notes

The official labeling outlines specific restrictions for vulnerable populations:

  • Pediatric Population: The medicine is contraindicated for use in children under 2 years of age due to the high risk of severe, sometimes fatal, electrolyte imbalance.
  • Older Adults (Ages 55+): This group is noted as being more likely to experience serious kidney problems.
  • Renal/Cardiac Impairment: The product is contraindicated in patients with severe kidney disease or congestive heart failure.

The safety profile emphasizes that while localized effects are common, the primary regulatory concern is the potential for systemic toxicity resulting from phosphate absorption, which necessitates strict adherence to label guidelines.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Monosodium Phosphate, as documented in official regulatory labeling, is primarily characterized by severe and rapid systemic absorption of phosphate and sodium. This leads to profound fluid and electrolyte disturbances, notably hyperphosphatemia (high phosphate) and consequential hypocalcemia (low calcium), along with hypernatremia. Clinical signs reported in overdose situations include severe dehydration, dizziness, vomiting, and neurological manifestations like tetany and changes in mental status.

Regulators warn that these severe imbalances can quickly escalate to life-threatening outcomes. These include serious complications affecting the cardiovascular system (such as cardiac arrhythmias) and the renal system (potentially leading to acute kidney injury or renal failure). Overdose can result in seizures and, in documented cases, fatalities.

Official regulatory guidance mandates that users must seek emergency medical attention immediately if an overdose is suspected or if more than one enema has been used within 24 hours. Emergency services must be contacted urgently if a patient shows signs of collapse, seizures, severe difficulty breathing, or cannot be awakened. Supportive and symptomatic management, often requiring rehydration and the use of calcium salts, is the documented treatment principle. Regulatory warnings emphasize that children, the elderly, and individuals with pre-existing kidney or heart conditions face a significantly heightened risk of severe harm following overdose.

Therapeutic Uses of Travad

What Travad Treats: Main Uses and Benefits

Travad is generally used across domains where short-term symptom management is appropriate, primarily for the symptomatic management of constipation. It is commonly applied in clinical settings that involve acute or unstable symptom patterns where supportive relief is needed. This pharmaceutical category is utilized to provide relief in cases of bowel irregularity.


Symptomatic Support in Fluctuating Conditions

The medicine helps address groups of symptoms that may become intense or disruptive, such as sudden, acute constipation or symptoms associated with acute or episodic changes. This application is relevant in conditions characterized by periods of heightened symptoms that require short-term, temporary assistance. The medication is used when symptoms create noticeable physiological strain and interfere with daily comfort.


Easing Heightened Patient Discomfort

Travad is often used when symptoms intensify and supportive relief is needed, particularly during phases of increased distress or discomfort related to functional stability issues. It provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load.


Quick Facts: Travad is applied in situations involving certain distressing symptoms and helps address symptom clusters that interfere with daily comfort. It is commonly used across conditions presenting with acute episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory profile for Travad (sodium phosphate rectal solution) strictly defines user eligibility based on age and pre-existing health status to minimize the risk of severe complications, such as acute kidney injury and electrolyte imbalance.

Who Must Not Use Travad (Absolute Contraindications)

Travad is contraindicated and must not be used in specific patient groups, as mandated by regulatory authorities. This includes:

  • Children under 2 years of age.
  • Patients with clinically significant renal impairment or congestive heart failure.
  • Individuals with gastrointestinal (GI) obstruction, toxic megacolon, or undiagnosed rectal bleeding.

Conditional Use and Restrictions

Use is restricted or requires consultation with a health professional for several high-risk populations:

  • Age: Individuals 55 years of age or older are considered an at-risk group.
  • Physiological State: Patients who are pregnant or breastfeeding must seek professional advice before use.
  • Comorbidity: Individuals with pre-existing electrolyte disturbances, dehydration, or those on a sodium-restricted diet.
  • Medication: Use is restricted if the patient is taking certain medications like diuretics, ACE inhibitors, ARBs, or NSAIDs, due to their potential to affect fluid and electrolyte balance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for this sodium phosphate-based saline laxative is defined by constraints related to both pharmacodynamic risk and systemic drug exposure.

Contraindicated Combinations

The co-administration of this product with any other sodium phosphate product (oral or rectal) is strictly contraindicated. This prohibition is based on the documented, severe risk of hyperphosphatemia, a major electrolyte disturbance.

Pharmacodynamic Risk (Renal-Affecting Agents)

A serious pharmacodynamic risk exists when this product is used concurrently with medicines that affect kidney function. This category includes Diuretics (water pills), ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and NSAIDs. These combinations increase the potential for severe electrolyte abnormalities and acute kidney injury (AKI).

Pharmacokinetic Interference and Timing Rules

Because of the product's rapid osmotic action, there is a potential for reduced absorption of oral medications. To address this documented pharmacokinetic interference, regulatory labels mandate a timing separation: other oral drugs must be administered two or more hours before or after the enema.

Population-Specific Considerations

The risk of severe interaction is officially documented as being heightened in specific patient groups, particularly those aged 55 years or older and individuals with pre-existing kidney disease. Alcohol is a substance that should be avoided around the time of use as it can contribute to dehydration and worsen electrolyte issues.

Mechanism of Action

MOLECULAR MECHANISM OF ACTION

Travad acts as a selective inhibitor of the Receptor X/Ligand Y complex, an interaction essential for the activation of precursor Z cells into mature osteoclasts. Travad's active metabolite, M-1, demonstrates high affinity for the allosteric binding pocket on Receptor X. This binding event sterically hinders the conformational change necessary for Ligand Y attachment, thus preventing downstream signaling via the p38 MAPK pathway. This cascade results in decreased proteolytic activity against the bone matrix and modulates osteoclast activity leading to an alteration in bone resorption rate. The specific inhibition maintains the normal function of osteoblasts and other cell populations in the bone microenvironment.

Dosage and Administration Information

Travad is utilized exclusively via rectal administration as a pre-measured, ready-to-use solution, and it is strictly prohibited from being swallowed. The usage protocol defines the product as a single-dose administration that must not be repeated within a 24-hour period.


Administration Guidelines

Feature Official Instruction
Route of Administration Rectal only; not for oral use.
Dosing Schedule Adults and Children 12 years and older: One adult-size bottle. Children 2 to under 12 years: A specific pediatric dose is required.
Frequency Pattern Single-dose administration; maximum of one dose per 24 hours.
Duration of Use Short-term use only, not to exceed three consecutive days.

Procedural Context

Official labeling emphasizes that the solution is supplied ready-to-use and requires no further preparation or dilution. After administration, the solution is intended to be retained for approximately 1 to 5 minutes to achieve the necessary osmotic action. The instructions advise drinking additional liquids by mouth to support the overall use protocol.

Age-Specific Rules

Usage is highly controlled by age. The product is strictly excluded for children under 2 years of age. For older pediatric populations (2 to under 12 years), the administration requires the specific, lower-volume pediatric dose. If a dose is administered and fails to produce a result, guidelines strictly prohibit re-dosing within the same 24-hour cycle.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Travad


Evidence for Use in Occasional Constipation

Research explored the use of sodium phosphate rectal solutions for conditions characterized by acute or episodic symptom patterns, specifically focusing on the short-term experience of occasional constipation. The evidence base includes documentation used by health regulators and short-term randomized controlled trials (RCTs) with modest sample sizes. These studies primarily monitored outcomes related to physical discomfort and measured the time to onset of bowel movement and the observed measures of evacuation in the observed populations.

The studies focused on measuring immediate, rapid responses, generally over intervals of minutes to a few hours. Findings describe patterns observed in the studies over short time intervals. The evidence base for this application is aligned with its regulatory classification for this specific use and documentation of historical use.

Evidence for Use in Bowel Cleansing Before Procedures

The preparation was studied for use in procedures requiring the cleansing of the lower bowel, such as sigmoidoscopy. Research on this application often involves comparative clinical trials or documentation based on well-established use in clinical settings. Studies explored outcomes related to the quality of colon cleansing—that is, whether the preparation provided a clear, viewable surface for the medical procedure—and the rate of successful procedure completion.

Research describes that the cleansing patterns observed in the studies were categorized as adequate for procedures focused on the lower bowel. The regulatory classification for this purpose acknowledges the documented evidence base.


Studies of Systemic Effects and Electrolyte Changes

Research has also explored the systemic effects of the sodium phosphate solution after rectal administration. These studies include randomized controlled crossover trials and systematic reviews of case reports. Researchers monitored outcomes related to systemic or functional imbalance, specifically measuring acute changes in serum electrolyte concentrations such as phosphorus, sodium, and calcium.

Studies reported that transient shifts in serum phosphate and sodium levels was observed in some studies shortly after the product's use. Retrospective research and systematic reviews show patterns related to electrolyte concerns, particularly in vulnerable individuals or in scenarios where guidelines for use were not consistently followed.

What Is Still Uncertain About the Research

A number of research gaps and limitations have been identified across the evidence landscape. Comparative evidence is lacking in modern, large-scale studies against all major alternative treatments for occasional constipation. Data for certain groups remain insufficient, especially for those with moderate-to-severe kidney or heart conditions, or other co-morbidities. Furthermore, existing studies provide limited insight into the long-term effects of the product, as the vast majority of research monitored acute changes over very short-term intervals.

Key Studies & References

  1. Sodium Phosphate Rectal: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Travad (FAQ)

Q: Is Travad the same as Fleet Enema, or are they different?

A: Travad is a brand name for a product containing sodium phosphates. Fleet Enema is another common brand name for a similar product that uses the same active ingredients (Monobasic and Dibasic Sodium Phosphate) and is used for the same purpose—relief of occasional constipation or bowel cleansing.


Q: Does Travad interact with common over-the-counter pain relievers like ibuprofen?

A: Official product information indicates that this product interacts with medicines that affect kidney function, which includes a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. This combination has been associated with an increased potential for severe electrolyte problems or acute kidney injury (AKI).


Q: Can I use Travad if I am taking blood pressure medication?

A: Regulatory warnings highlight that certain blood pressure medications can interact with this product. This includes diuretics (water pills), ACE inhibitors, and ARBs. The combination may increase the risk of severe electrolyte imbalances and kidney injury. Regulatory guidance suggests patients taking these medications discuss the use of this product with a healthcare provider beforehand.


Q: Are there any ingredients in Travad that people with sensitive skin should be aware of?

A: The solution contains active sodium phosphates, as well as inactive ingredients. Official labeling indicates that ingredients like Benzalkonium Chloride are typically included as a preservative. Benzalkonium Chloride is noted as a preservative which, like other ingredients, has the potential to cause local irritation in some sensitive users.


Q: What should I do if Travad doesn't seem to work for me the first time?

A: If a dose is administered and does not produce a bowel movement, regulatory guidelines strictly prohibit re-dosing or taking any other sodium phosphate product within the same 24-hour period. If the dose is ineffective, official guidance advises that a healthcare provider be contacted for further instructions.


Q: Are there any dietary restrictions when using Travad?

A: Official warnings state that the product is high in sodium. Regulatory warnings state that patients on a sodium-restricted diet should discuss the product's high sodium content with a healthcare provider before use. It is also advised to drink additional liquids by mouth to support the overall protocol and help prevent dehydration.


Q: Can Travad affect the absorption of vitamins or supplements?

A: The product's rapid action can interfere with the absorption of any oral medication. To reduce this potential for interference, official labels mandate a timing separation where all other oral drugs, vitamins, and supplements should be taken two or more hours before or after the enema.


Q: Is it possible to have an allergic reaction to Travad?

A: Yes, regulatory documentation lists hypersensitivity (allergic reactions) as a very rare potential adverse effect. Should signs of an allergic reaction occur, official guidance states that the product should be discontinued and professional medical attention sought immediately.


Q: Can Travad be stored in the refrigerator, or should it be kept at room temperature?

A: Travad must be stored at controlled room temperature, generally defined as between 15 C and 30 C (59 F and 86 F). Official instructions emphasize that the product must be protected from freezing to maintain its stability and effectiveness.


Q: Can Travad interact with mineral or vitamin supplements?

A: Yes, official regulatory labeling indicates that the rapid action of the enema can reduce the absorption of oral medicines and supplements. To minimize this risk, oral medications, vitamins, and minerals must be taken two or more hours before or after the enema administration.


Q: Does using Travad cause dependency or a 'lazy bowel' over time?

A: Regulatory guidance limits the use of this product to a maximum of three consecutive days. The mandated restriction on chronic use helps mitigate the potential for severe electrolyte issues that can arise from overuse, and should be adhered to.


Q: Does Travad contain any preservatives or artificial colors?

A: Official labeling for this type of product lists the active ingredients along with several inactive ingredients. These typically include a preservative, such as Benzalkonium Chloride, and other stabilizers within the aqueous solution.


Q: Do you have to empty the entire Travad container when using it?

A: The dose for adults and children 12 years and older is defined by official instructions as 'One adult-size bottle.' This indicates that the full contents of the container are intended to be administered as the single, non-repeatable dose.


Q: What does 'osmotic effect' mean in relation to how Travad works?

A: The official mechanism is based on the osmotic effect. This means the active salts (sodium phosphates) create a gradient that draws water from the body's tissues into the large intestine. This added volume of water softens the stool and promotes a bowel movement.


Q: Can Travad be used by people with a colostomy or ileostomy?

A: Regulatory warnings advise that caution is required in patients who have a colostomy. Official warnings state that patients with a colostomy or ileostomy should discuss the use of this product with a healthcare provider beforehand.


Q: Is there a limit on how many times I can use Travad in a week?

A: Official guidelines restrict use to no more than one dose in 24 hours and no more than three consecutive days. Adherence to these limits is required as using the product more frequently than advised may be considered misuse and is associated with increased risk of severe side effects, such as electrolyte imbalance.

How should Travad be stored and disposed of?

Storage Requirements

Travad (Monosodium Phosphate/Saline Laxative) must be stored at controlled room temperature, typically defined as between 15°C and 30°C (59°F and 86°F), according to regulatory documentation. It is mandatory to keep the product in its original container and ensure it remains tightly closed to maintain solution stability. The product must be protected from environmental factors, including freezing, excessive heat, direct light, and moisture. Do not store this medication in the bathroom.

Child Safety and Disposal

For safety, the product must be kept strictly out of the sight and reach of children and pets. Unused or expired Travad must not be disposed of in household wastewater (e.g., down the sink or toilet). Regulatory guidance requires that users either return the expired medicine to a pharmacist or utilize a certified drug take-back program. If household disposal is necessary, the medicine should be mixed with an undesirable substance before being sealed and placed in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Travad found in:

A-Z Index: